<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/38/8126" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/38/8126/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/38/8126/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_8126"><akn:num>8126</akn:num><akn:heading>Limitation on prices of drugs procured by Department and certain other Federal agencies</akn:heading><akn:content><akn:p>§ 8126. Limitation on prices of drugs procured by Department and certain other Federal agencies(a) Each manufacturer of covered drugs shall enter into a master agreement with the Secretary under which—(1) beginning January 1, 1993, the manufacturer shall make available for procurement on the Federal Supply Schedule of the General Services Administration each covered drug of the manufacturer;

(2) with respect to each covered drug of the manufacturer procured by a Federal agency described in subsection (b) on or after January 1, 1993, that is purchased under depot contracting systems or listed on the Federal Supply Schedule, the manufacturer has entered into and has in effect a pharmaceutical pricing agreement with the Secretary (or the Federal agency involved, if the Secretary delegates to the Federal agency the authority to enter into such a pharmaceutical pricing agreement) under which the price charged during the one-year period beginning on the date on which the agreement takes effect may not exceed 76 percent of the non-Federal average manufacturer price (less the amount of any additional discount required under subsection (c)) during the one-year period ending one month before such date (or, in the case of a covered drug for which sufficient data for determining the non-Federal average manufacturer price during such period are not available, during such period as the Secretary considers appropriate), except that such price may nominally exceed such amount if found by the Secretary to be in the best interests of the Department or such Federal agencies;

(3) with respect to each covered drug of the manufacturer procured by a State home receiving funds under section 1741 of this title, the price charged may not exceed the price charged under the Federal Supply Schedule at the time the drug is procured; and

(4) unless the manufacturer meets the requirements of paragraphs (1), (2), and (3), the manufacturer may not receive payment for the purchase of drugs or biol</akn:p></akn:content><akn:subsection eId="subsec_8126_a"><akn:num>(a)</akn:num><akn:content><akn:p>(a) Each manufacturer of covered drugs shall enter into a master agreement with the Secretary under which—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_8126_b"><akn:num>(b)</akn:num><akn:content><akn:p>(b) The Federal agencies described in this subsection are as follows:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_8126_c"><akn:num>(c)</akn:num><akn:content><akn:p>(c) With respect to any covered drug the price of which is determined in accordance with a pharmaceutical pricing agreement entered into pursuant to subsection (a)(2), beginning on or after January 1, 1993, the manufacturer shall provide a discount in an amount equal to the amount by which the change in non-Federal price exceeds the amount equal to—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_8126_d"><akn:num>(d)</akn:num><akn:content><akn:p>(d) In the case of a covered drug of a manufacturer that has entered into a multi-year contract with the Secretary under subsection (a)(2) for the procurement of the drug—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_8126_e"><akn:num>(e)</akn:num><akn:content><akn:p>(e)</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_8126_f"><akn:num>(f)</akn:num><akn:content><akn:p>(f) The Secretary shall supply to the Secretary of Health and Human Services—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_8126_g"><akn:num>(g)</akn:num><akn:content><akn:p>(g)</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_8126_h"><akn:num>(h)</akn:num><akn:content><akn:p>(h) In this section:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_8126_i"><akn:num>(i)</akn:num><akn:content><akn:p>(i)</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>